In Apri 2020, the FDA requested all manufacturers pull Zantac from store shelves immediately after an ongoing investigation found that levels of the contaminant in the medication increase over time and when stored at higher temperatures.
In September 2019, the FDA announced a voluntary recall of certain lots of Zantac (also known as the generic Ranitidine) by manufacturer Sandoz for containing N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen.
In November 2019, the recall was expanded to include additional lots of Zantac/Ranitidine manufactured by Amneal Pharmaceuticals LLC and Lannett Company. According to recall information from the FDA, the medication manufactured by Amneal Pharmaceutials contains unacceptable levels of NDMA. Most recently, Golden State Medical Supply, Inc. issued a voluntary nationwide recall of Ranitidine Hydrocholride 150mg and 300mg capsules manufactured by Novitium Pharma, LLC, adding to the growing list of recalled Ranitidine.
In response to the recall, numerous retailers, such as Walmart and Walgreens, have pulled Zantac from their shelves.